Antimicrobial resistance in hospital-acquired gram-negative bacterial infections

Chest

Volumn 147, Issue 5, 2015, Pages 1413-1421

  Mehrad, Borna ^a   Clark, Nina M ^b   Zhanel, George G ^c   Lynch, Joseph P ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFEPIME; CEFMETAZOLE; CEFOTETAN; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLAVULANIC ACID; COLISTIN; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; MEROPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; RIFAMYCIN; SULBACTAM; TAZOBACTAM; TIGECYCLINE;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; DEBRIDEMENT; ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; CROSS INFECTION; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY;

CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84929486123     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2171     Document Type: Article

References (80)

1. D'Costa VM , King CE , K alan L , et al. Antibiotic resistance is ancient. Nature. 2011 ; 477 (7365): 457-461.
2. Nesme J , Cécillon S , Delmont TO , Monier JM , Vogel TM , Simonet P. Large-scale meta genomic-based study of antibiotic resistance in the environment. Curr Biol. 2014 ; 24 (10): 1096-1100.
3. Vincent JL , Rello J , Marshall J , et al ; EPIC II Group of Investigators. Internatio nal study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009 ; 302 (21): 2323-2329.
4. Cantón R , Akó va M , Carmeli Y , et al ; European Network on Carbapenemases. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012 ; 18 (5): 413-431.
5. Petty N K , Ben Zakour NL , Stanton-Cook M , et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A. 2014 ; 111 (15): 5694-5699.
6. Landers TF , Cohe n B , Wittum TE , Larson EL. A review of antibiotic use in food animals: perspective, policy, and potential. Public Health Rep. 2012 ; 127 (1): 4-22.
7. World Health Organization. Antimicrobial R esistance Global Report on Surveillance. Geneva, Switzerland: World Health Organization ; 2014.
8. Rosenthal VD,Bijie H,Maki DG,et al INICC members. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009 Am J Infect Control. 2012 40 (5) 396-407.
9. Sievert DM , Ricks P , Edwards JR , et al ; National Healthcare Safety Net work (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcareassociated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013 ; 34 (1): 1-14.
10. Zarb P , Coignard B , Griskeviciene J , et al ; National Contact Points for the ECDC pilot point prevalence survey; Hos pital Contact Points for the ECDC pilot point prevalence survey. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-Associated infections and antimicrobial use. Euro Surveill. 2012 ; 17 (4 6): 17.
11. Tablan OC , Anderson LJ , Besser R , Bridges C , Hajjeh R ; CDC; Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-Associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004 ; 53 (RR-3): 1-36.
12. Centers for Disease Control and Prevention. Antibiotic Resistance Th reats in the United States, 2013. Atlanta, GA : Centers for Disease Control and Prevention ; 2013.
13. Fujitani S , Sun HY , Yu VL , Weingarten JA. Pneumonia due to Pseudomonas aeruginosa : part I: epidemiology, clinical diagnosis, and source. Chest. 2011 ; 139 (4): 909-919.
14. Sun HY , Fujitani S , Quintiliani R , Yu VL. Pneumonia due to Pseudomonas aeruginosa : part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest. 2011 ; 139 (5): 1172-1185.
15. Laurent C , Rodriguez-Villalobos H , Rost F , et al. Intensive care unit outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae controlled by cohorting patients and reinforcing infection control me asures. Infect Control Hosp Epidemiol. 2008 ; 29 (6): 517-524.
16. Di Yacovo S , Garcia-Vidal C , Viasus D , et al. Clinical features, etiology, and outcomes of community-Acquired pneumoni a in patients with diabetes mellitus. Medicine (Baltimore). 2013 ; 92 (1): 42-50.
17. Oteo J , Pérez-Vázquez M , Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidem iology and clinical impact. Curr Opin Infect Dis. 2010 ; 23 (4): 320-326.
18. Piednoir E , Th ibon P , Borderan GC , et al. Long-term clinical and economic benefi ts associated with the management of a nosocomial outbreak resulting from extended-spectrum beta-lactamaseproducing Klebsiella pneumoniae. Crit Ca re Med. 2011 ; 39 (12): 2672-2677.
19. Lynch JP III , Clark NM , Zhanel GG. Evolution of antimicrobial resistance among Enterobacteriaceae (focus on extended spectrum b-lactamases and carbapenemases). Expert Opin Pharmacother. 2013 ; 14 (2): 199-210.
20. Lee YT , Kuo SC , Yang SP , et al. Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis : a si ngle or two distinct clinical entities? Clin Microbiol Infect. 2013 ; 19 (7): 640-645.
21. Gaynes R , Edwards JR ; National Nosocomial Infections Surveillance System. Overview of nosocomial infections caus ed by gram-negative bacilli. Clin Infect Dis. 2005 ; 41 (6): 848-854.
22. Sader HS , Farrell DJ , Flamm RK , Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). Diagn Microbiol Infect Dis. 2014; 78(4): 443-448.
23. Falagas ME , Kasiakou SK , Rafailidis PI , Zo uglakis G , Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother. 2006 ; 57 (6): 1251-1254.
24. Kempf M , Rolain JM. Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents. 2012 ; 39 (2): 105-114.
25. Lee YT , Kuo SC , Yang SP , et al. Impact of appropriate antimicrobial therapy on mortality associated with Acinetobacter baumannii bacteremia: relation to severity of infection. Clin Infect Dis. 2012 ; 55 (2): 209-215.
26. Kallen AJ , Hidron AI , Patel J , Srinivasan A. Multidrug resistance among gram-negative pathogens that caused healthcare-Associated infections reported to the National Healthcare Safety Network, 2006-2008. Infect Control Hosp Epidemiol. 2010 ; 31 (5): 528-531.
27. Brooke JS. S tenotrophomonas maltophilia : an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012 ; 25 (1): 2-41.
28. Falagas ME , Kastoris AC , Vouloumanou EK , Rafailidis PI , Kapaskelis AM , Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of t he literature. Future Microbiol. 2009 ; 4 (9): 1103-1109.
29. Mori M , Tsunemine H , Imada K , Ito K , Kodaka T , Takahashi T. Life-threatening hemorrhagic pneumonia caused by Sten otrophomonas maltophilia in the treatment of hematologic diseases. Ann Hematol. 2014 ; 93 (6): 901-911.
30. Payne GW,Vandamme P,Morgan SH,et al. Development of a recA gene-based identifi cation approach for the entire Burkholderia genus Appl Environ Microbiol. 2005 71, 7, 3917-3927.
31. Liao CH , Chang HT , Lai CC , et al. Clinical characteristics and outcomes of pati ents with Burkholderia cepacia bacteremia in an intensive care unit. Diagn Microbiol Infect Dis. 2011 ; 70 (2): 260-266.
32. Estivariz CF , Bhatti LI , Pati R , et al. An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest. 2006 ; 130 (5): 1346-1353.
33. Bressler AM , Kaye KS , LiPuma JJ , et al. Risk factors for Burkholderia cepacia complex bacteremia among intensive care unit patients without cystic fi brosis: a case-control study. Infect Control Hosp Epidemiol. 2007 ; 28 (8): 951-958.
34. Gó mez-Cerezo J , Suárez I , Ríos JJ , et al. Achromobacter xylosoxidans bacteremia: a 10-year analysis of 54 cases. Eur J Clin Microbiol Infect Dis. 2003 ; 22 (6): 360-363.
35. Aisenberg G , Rolston KV , Safdar A. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer. 2004 ; 101 (9): 2134-2140.
36. Claassen SL , Reese JM , Mysliwiec V , Mahlen SD. Achromobacter xylosoxidans infection presenting as a pulmonary nodule mimicking cancer. J Clin Microbiol. 2011 ; 49 (7): 2751-2754 .
37. Bush K , Jacoby GA. Updated functional classifi cation of betalactamases. Antimicrob Agents Chemother. 2010 ; 54 (3): 969-976.
38. Humeniuk C , Arlet G , Gautier V , Grimont P , Labia R , Philippon A. Beta-lactamases of Kluyvera ascorbata , probable progenitors of some plasmid-encoded CTX-M types. Antimicrob Agents Chemother. 2002 ; 46 (9): 3045-3049.
39. Winokur PL , Canton R , Casellas JM , Legakis N. Variations in the prevalence of strains expressing an extended-spectrum betalactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacifi c r egion. Clin Infect Dis. 2001; 32(suppl 2): S94-S103.
40. Rossi F , Baquero F , Hsueh PR , et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram-negative bacilli isolated fr om patients with intra-Abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother. 2006 ; 58 (1): 205-210.
41. National Nosocomial Infecti ons Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004 ; 32 (8): 470-485.
42. Peirano G , van der Bij AK , Gregson DB , Pitout JD. Molecular epidemiology over an 11-year period (2000 to 2010) of extendedspectrum b-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadi an region. J Clin Microbiol. 2012 ; 50 (2): 294-299.
43. Wiener J , Quinn JP , Bradford PA , et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA. 1999 ; 281 (6): 517-523.
44. Paterson DL , Ko WC , Von Gottberg A , et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase p roduction in nosocomial infections. Ann Intern Med. 2004 ; 140 (1): 26-32.
45. Park YS , Adams-Haduch JM , Shutt KA , et al. Clinical and microbiologic characteristics of cephalosporin-res istant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother. 2012 ; 56 (4): 1870-1876.
46. Rodríguez-Baño J , Picón E , Gijón P , et al ; Spanish Network for Research in Infectious Diseases (REIPI). Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli : risk factors and prognosis. Clin Infect Dis. 2010 ; 50 (1) : 40-48.
47. Lee JA , Kang CI , Joo EJ , et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum b-lactamase-producing Klebsiella pneumoniae. Microb Drug Resist. 2011 ; 17 (2): 267-273.
48. Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep. 2013 ; 62 (9): 165-170.
49. Patel G , Huprikar S , Factor SH , Jenkins SG , Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp E pidemiol. 2008 ; 29 (12): 1099-1106.
50. Yigit H , Queenan AM , Anderson GJ , et al. Novel carbapenemhydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoni ae. Antimicrob Agents Chemother. 2001 ; 45 (4): 1151-1161.
51. Healthcare-Associated Infections (HAIs). updated February 2014. Centers for Disease Control and Prevention website. http://www. cdc.gov/h ai/organisms/cre/TrackingCRE.html. Accessed August 30, 2014.
52. Yong D , Toleman MA , Giske CG , et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esteras e gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009 ; 53 (12): 5046-5054.
53. Kumarasamy KK , Toleman MA , Walsh TR , et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010 ; 10 (9): 597-602.
54. Centers for Disease Control and Prevention (CDC). Notes from the Field: New Delhi metallo-b-lactamase-producing Escherichia coli associated with endoscopic retrograde cholangiopancreatography-Illinois, 2013. MMWR Morb Mortal Wkly Rep. 2014 ; 62 (51-52): 1051.
55. Berrazeg M , Diene S , Medjahed L , et al. New Delhi Metallo-betalactamase around the world: an eReview using Google Maps. Euro Surveill. 2014 ; 19 (20): 19.
56. Centers for Disease Control and Prevention (CDC). Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase-United States, 2010. MMWR Morb Mortal Wkly Rep. 2010 ; 59 (24): 750.
57. Goessens WH , van der Bij AK , van Boxtel R , et al. Antibiotic trapping by plasmid-encoded CMY-2 b-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli. Antimicrob Agents Chemother. 2013 ; 57 (8): 3941-3949.
58. Endimiani A , Luzzaro F , Perilli M , et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofl oxacin. Clin Infect Dis. 2004 ; 38 (2): 243-251.
59. Paterson DL , Ko WC , Von Gottberg A , et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis. 2004; 39(1): 31-37.
60. Kaniga K , Flamm R , Tong SY , Lee M , Friedland I , Redman R. Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofl oxacinresistant Enterobacteriaceae: an alysis of six phase 3 clinical studies. Antimicrob Agents Chemother. 2010 ; 54 (5): 2119-2124.
61. Fong JJ , RoséL , Radigan EA. Clinical outcomes with ertapenem as a fi rst-line treatment option of infections caused by extendedspectrum b-lactamase producing gram-negative bacteria. Ann Pharmacother. 2012 ; 46 (3): 347-352.
62. Guet-Revillet H , Emirian A , Groh M , et al. Pharmacologi cal study of cefoxitin as an alternative antibiotic therapy to carbapenems in treatment of urinary tract infections due to extended-spectrumb-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2014 ; 58 (8): 4899-49 01.
63. Frakking FN , Rottier WC , Dorigo-Zetsma JW , et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-b-lactamase-producing bacteria. Antimicrob Agents Chemothe r. 2013 ; 57 (7): 3092-3099.
64. Ma L , Lin CJ , Chen JH , et al ; Taiwan Surveillance of Antimicrobial Resistance Project. Widespread dissemination of aminoglycoside resistance genes armA and rmtB in Klebsiella pneumoniae isolates in Taiwan producing CTX-M-type extended-spectrum betalactamases. Antimicrob Agents Chemother. 2009 ; 53 (1): 104-111.
65. Denys GA , Callister SM , Dowzicky MJ. Antimi crobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.). Ann Clin Microbiol Antimicrob. 2013 ; 12 : 24.
66. Prasad P , Sun J , Danner RL , Natanson C. Excess deaths associated with tigecycline aft er approval based on noninferiority trials. Clin Infect Dis. 2012 ; 54 (12): 1699-1709.
67. Falagas ME , Lourida P , Poulikakos P , Rafailidis PI , Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chem other. 2014 ; 58 (2): 654-663.
68. Lim LM , Ly N , Anderson D , et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010 ; 30 (12): 1279-1291.
69. Garonzik SM , Li J , Th amlikitkul V , et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing s uggestions for various categories of patients. Antimicrob Agents Chemother. 2011 ; 55 (7): 3284-3294.
70. Pontikis K , Karaiskos I , Bastani S , et al. Outcomes of critically ill intensive care uni t patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemaseproducing gram-negative bacteria. Int J Antimicrob Agents. 2014 ; 43 (1): 52-59.
71. Garna cho-Montero J , Sa-Borges M , Sole-Violan J , et al. Optimal management therapy for Pseudomonas aeruginosa ventilatorassociated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007 ; 35 (8): 1888-1895.
72. Bowers DR,Liew YX,Lye DC,Kwa AL,Hsu LY,Tam VH. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeru ginosa bacteremia Antimicrob Agents Chemother. 2013, 57, 3, 1270-1274.
73. Koft eridis DP , Alexopoulou C , Valachis A , et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for t he treatment of ventilator-Associated pneumonia: a matched case-control study. Clin Infect Dis. 2010 ; 51 (11): 1238-1244.
74. Tumbarello M , De Pascale G , Trecarichi EM , et al. Eff ect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-Associated pneumonia caused by colistin-only suscep tible gram-negative bacteria. Chest. 2013 ; 144 (6): 1768-1775.
75. Chu H , Zhao L , Wang M , Liu Y , Gui T , Zhang J. Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-Analysis. Braz J Infect Dis. 2013 ; 17 (4): 389-394.
76. O'Grady NP , Alexander M , Burns LA , et al. Guidelines for the prevention of intravascular catheter-related infections. 2011. Centers for Disease Control and Prevention website. http://www. cdc.gov/hicpac/pdf/guidelines/bsi-guidelines-2011.pdf. Accessed August 30, 2014.
77. Coffi n SE , Klompas M , Classen D , et al . Strategies to prevent ventilator-Associated pneumonia in acute care hospitals. Infect Control Hosp Epidemiol. 2008; 29(suppl 1): S31-S40.
78. Silvestri L , van Saene HK , Zandstra DF , Marshall JC , Gregori D , Gullo A. Impact of selective decontamination of the digestive tract on multiple organ dysfunction syndrome: systematic review of randomized controlled trials. Crit Care Med. 2010 ; 38 (5): 1370-1376.
79. Klompas M , Speck K , Howell MD , Greene LR , Berenholtz SM. Reappraisal of routine oral care with chlorhexidine gluconate for patients receiving mechanical ventilation: systematic review and meta-Analysis. JAMA I ntern Med. 2014 ; 174 (5): 751-761.
80. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America; Pediatric Infectious Diseases Society. Policy statement on antimicrobial steward ship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol. 2012 ; 33 (4): 322-327.